Picoplatin

Picoplatin

Names
IUPAC name azane; 2-methylpyridine; platinum(2+); dichloride
Identifiers
CAS Number	181630-15-9 Y
3D model (Jmol)	Interactive image
ChemSpider	154428 N
ECHA InfoCard	100.205.233
PubChem	177358
UNII	B5TAN0L720 Y
InChI InChI=1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2 N Key: IIMIOEBMYPRQGU-UHFFFAOYSA-L N InChI=1/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2 Key: IIMIOEBMYPRQGU-NUQVWONBAG
SMILES Cc1ccccn1.N.[Cl-].[Cl-].[Pt+2]
Properties
Chemical formula	C6H10Cl2N2Pt
Molar mass	376.14 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors.^[1]

In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.^[2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.^[3] Hopes are now pinned on its use for metastatic colorectal cancer.^[4]

References